Patents by Inventor Louis Buscail

Louis Buscail has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for predicting pancreatic cancer treatment response
    Patent number: 10760135
    Abstract: The present invention relates to methods for predicting pancreatic cancer treatment response.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: September 1, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Pierre Cordelier, Louis Buscail, Frédéric Lopez
  • METHODS FOR PREDICTING PANCREATIC CANCER TREATMENT RESPONSE
    Publication number: 20190024186
    Abstract: The present invention relates to methods for predicting pancreatic cancer treatment response.
    Type: Application
    Filed: January 13, 2016
    Publication date: January 24, 2019
    Inventors: Pierre CORDELIER, Louis BUSCAIL, Frédéric LOPEZ
  • Methods for the Diagnosis of Pancreatic Cancer
    Publication number: 20180010194
    Abstract: The present invention relates to the diagnosis of pancreatic cancer, in particular to a salivary mi RNA for use in the diagnosis of pancreatic cancer.
    Type: Application
    Filed: January 12, 2016
    Publication date: January 11, 2018
    Inventors: Pierre Cordelier, Louis Buscail, Marine Humeau
  • Somatostatin 2 receptor (sst2), deoxycytidine kinase (dck) and uridine monophosphate kinase (umk) pancreatic gene therapy
    Patent number: 9364494
    Abstract: The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: June 14, 2016
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Cayla
    Inventors: Louis Buscail, Gérard Tiraby, Fabienne Vernejoul, Christiane Susini, Daniel Drocourt
  • COMBINATION PRODUCTS FOR TREATING CANCER
    Publication number: 20150190480
    Abstract: The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.
    Type: Application
    Filed: January 2, 2015
    Publication date: July 9, 2015
    Inventors: LOUIS BUSCAIL, GERARD TIRABY, FABIENNE VERNEJOUL, CHRISTIANE SUSINI, DANIEL DROCOURT
  • Combination Products For Treating Cancer
    Publication number: 20100222418
    Abstract: The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.
    Type: Application
    Filed: October 10, 2008
    Publication date: September 2, 2010
    Applicants: CAYLA, Institut National De La Sante Et De La Recherche Medicale (Inserm)
    Inventors: Louis Buscail, Gerard Tiraby, Fabienne Vernejoul, Christiane Susini, Daniel Drocourt
  • USE OF CELLS DERIVED FROM ADIPOSE TISSUE FOR THE PREPARATION OF AN ANTI-TUMOR MEDICAMENT
    Publication number: 20090186007
    Abstract: Use of cells isolated from extramedullary white adipose tissue, selected from the group consisting of the stromal-vascular fraction and a subpopulation of said stromal-vascular fraction consisting of adherent cells, for the preparation of an anti-tumor medicament.
    Type: Application
    Filed: May 18, 2007
    Publication date: July 23, 2009
    Inventors: Pierre Cordelier, Louis Buscail, Louis Casteilla, Beatrice Cousin-Delarue, Luc Penicaud, Jean-Marie Peron